Mizoribine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Mizoribine
Accession Number
DB12617
Type
Small Molecule
Groups
Investigational
Description

Mizoribine has been investigated for the treatment of Rheumatoid Arthritis.

Structure
Thumb
Synonyms
  • BREDININ
Categories
UNII
4JR41A10VP
CAS number
50924-49-7
Weight
Average: 259.216
Monoisotopic: 259.080435163
Chemical Formula
C9H13N3O6
InChI Key
HZQDCMWJEBCWBR-UUOKFMHZSA-N
InChI
InChI=1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxy-1H-imidazole-4-carboxamide
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with 5-androstenedione.Experimental, Illicit
AbciximabMizoribine may increase the anticoagulant activities of Abciximab.Approved
AcebutololMizoribine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Mizoribine.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Acemetacin.Approved
AcenocoumarolMizoribine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
AceprometazineThe serum concentration of Aceprometazine can be increased when it is combined with Mizoribine.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mizoribine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mizoribine.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mizoribine.Approved, Vet Approved
AclarubicinMizoribine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mizoribine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alendronic acid.Approved
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
AliskirenMizoribine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Alminoprofen.Experimental
AlprenololMizoribine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mizoribine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Amcinonide.Approved
AmikacinMizoribine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMizoribine may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinMizoribine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMizoribine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Mizoribine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mizoribine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Mizoribine.Investigational
annamycinMizoribine may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Mizoribine.Approved
Antithrombin III humanMizoribine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanMizoribine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Mizoribine is combined with Apocynin.Investigational
ApramycinMizoribine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Mizoribine.Approved, Investigational
ArbekacinMizoribine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMizoribine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMizoribine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMizoribine may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Mizoribine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Atamestane.Investigational
AtenololMizoribine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Mizoribine.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mizoribine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mizoribine.Approved
BalsalazideMizoribine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mizoribine.Investigational
BecaplerminMizoribine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMizoribine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMizoribine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mizoribine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mizoribine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mizoribine.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mizoribine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Betamethasone.Approved, Vet Approved
BetaxololMizoribine may decrease the antihypertensive activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
BevantololMizoribine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mizoribine.Approved, Investigational
BisoprololMizoribine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMizoribine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BL-1020The serum concentration of BL-1020 can be increased when it is combined with Mizoribine.Investigational
BopindololMizoribine may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mizoribine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Mizoribine.Investigational
BucindololMizoribine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bufexamac.Experimental
BufuralolMizoribine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Bumadizone.Experimental
BumetanideMizoribine may decrease the diuretic activities of Bumetanide.Approved
BupranololMizoribine may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mizoribine.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Mizoribine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mizoribine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mizoribine.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Mizoribine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mizoribine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Mizoribine.Approved, Vet Approved, Withdrawn
CarteololMizoribine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMizoribine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Mizoribine.Experimental
CeliprololMizoribine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMizoribine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mizoribine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
ChlorproethazineThe serum concentration of Chlorproethazine can be increased when it is combined with Mizoribine.Experimental
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mizoribine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mizoribine.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mizoribine.Approved
CinoxacinMizoribine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidMizoribine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Mizoribine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mizoribine.Vet Approved
CloranololMizoribine may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mizoribine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Mizoribine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Cortisone acetate.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Mizoribine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Mizoribine.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mizoribine.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
CyclosporineMizoribine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Mizoribine.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Mizoribine.Investigational
Dabigatran etexilateMizoribine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMizoribine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMizoribine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapsoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dapsone.Approved, Investigational
DarexabanMizoribine may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinMizoribine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Mizoribine is combined with Deferasirox.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Mizoribine.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mizoribine.Approved
DesirudinMizoribine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mizoribine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mizoribine.Approved, Investigational
DextranMizoribine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Mizoribine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Mizoribine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Mizoribine may increase the anticoagulant activities of Dextran 75.Approved
DibekacinMizoribine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mizoribine.Approved, Vet Approved
DicoumarolMizoribine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mizoribine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mizoribine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mizoribine.Approved
DihydrostreptomycinMizoribine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mizoribine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mizoribine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mizoribine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mizoribine.Approved, Investigational
DoxorubicinMizoribine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMizoribine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Mizoribine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Mizoribine.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Mizoribine.Investigational
Edetic AcidMizoribine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMizoribine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mizoribine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mizoribine.Approved
EnoxacinMizoribine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinMizoribine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Mizoribine.Experimental
EpanololMizoribine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Mizoribine.Approved
EpirubicinMizoribine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMizoribine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mizoribine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mizoribine.Approved
EquileninThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Equilin.Approved
EsmololMizoribine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone sulfate.Approved
Etacrynic acidMizoribine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMizoribine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Mizoribine.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Mizoribine.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Mizoribine.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Mizoribine.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Mizoribine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mizoribine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mizoribine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Feprazone.Experimental
Ferulic acidMizoribine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mizoribine.Approved, Investigational
FingolimodMizoribine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinMizoribine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mizoribine.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fludrocortisone.Approved
FluindioneMizoribine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMizoribine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flumethasone.Approved, Vet Approved
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Mizoribine.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluorometholone.Approved
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Mizoribine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mizoribine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mizoribine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mizoribine.Approved, Nutraceutical, Vet Approved
FondaparinuxMizoribine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMizoribine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mizoribine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mizoribine.Approved
FramycetinMizoribine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMizoribine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Mizoribine.Investigational
GabexateMizoribine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMizoribine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMizoribine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mizoribine.Approved, Withdrawn
GemifloxacinMizoribine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMizoribine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMizoribine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMizoribine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Mizoribine.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Mizoribine.Experimental
GPX-150Mizoribine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinMizoribine may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Mizoribine is combined with Guacetisal.Experimental
HaloperidolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mizoribine is combined with HE3286.Investigational
HeparinMizoribine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Higenamine.Investigational
HydralazineMizoribine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mizoribine.Approved, Investigational
Hygromycin BMizoribine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Mizoribine.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Mizoribine.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Mizoribine.Approved
IdarubicinMizoribine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxMizoribine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mizoribine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Mizoribine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mizoribine.Approved
IndenololMizoribine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Mizoribine.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mizoribine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Mizoribine.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Mizoribine.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Mizoribine.Investigational
INNO-206Mizoribine may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mizoribine.Approved, Investigational
IsepamicinMizoribine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mizoribine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mizoribine is combined with Istaroxime.Investigational
KanamycinMizoribine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Mizoribine.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Mizoribine.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mizoribine.Approved
LabetalolMizoribine may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mizoribine.Experimental
LandiololMizoribine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Mizoribine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Mizoribine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Leflunomide.Approved, Investigational
LepirudinMizoribine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMizoribine may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololMizoribine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMizoribine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mizoribine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mizoribine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Mizoribine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Mizoribine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Mizoribine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mizoribine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mizoribine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mizoribine.Approved, Investigational
LumefantrineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Lumefantrine.Approved
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mizoribine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mizoribine.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mizoribine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Mizoribine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mizoribine.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mizoribine.Approved
MelagatranMizoribine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Mizoribine.Approved, Vet Approved
MepindololMizoribine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineMizoribine may increase the nephrotoxic activities of Mesalazine.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Mizoribine.Approved, Investigational
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Mizoribine.Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mizoribine.Approved
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Mizoribine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mizoribine.Approved
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Mizoribine.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mizoribine.Experimental
MetipranololMizoribine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine.Approved
MetoprololMizoribine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMizoribine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinMizoribine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mizoribine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mizoribine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Mofebutazone.Experimental
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Mizoribine.Approved, Investigational, Withdrawn
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mizoribine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mizoribine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine.Approved
NadololMizoribine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMizoribine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMizoribine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mizoribine.Approved
Nalidixic AcidMizoribine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Mizoribine.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mizoribine is combined with NCX 1022.Investigational
NeamineMizoribine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMizoribine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMizoribine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Mizoribine.Approved
NetilmicinMizoribine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mizoribine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mizoribine.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mizoribine.Investigational
NorfloxacinMizoribine may increase the neuroexcitatory activities of Norfloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Mizoribine.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mizoribine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mizoribine.Approved
OlsalazineMizoribine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mizoribine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Mizoribine.Vet Approved
OtamixabanMizoribine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mizoribine.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mizoribine.Approved
Oxolinic acidMizoribine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololMizoribine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mizoribine.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mizoribine.Approved, Vet Approved
PamidronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Paramethasone.Approved
ParomomycinMizoribine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Parthenolide.Investigational
PazufloxacinMizoribine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMizoribine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMizoribine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMizoribine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerazineThe serum concentration of Perazine can be increased when it is combined with Mizoribine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mizoribine.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Mizoribine.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mizoribine.Experimental
PhenindioneMizoribine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMizoribine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mizoribine.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mizoribine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mizoribine.Approved, Investigational
PindololMizoribine may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidMizoribine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinMizoribine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMizoribine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Mizoribine.Approved, Investigational
Piromidic acidMizoribine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mizoribine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pirprofen.Experimental
PlazomicinMizoribine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinMizoribine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mizoribine.Approved
PractololMizoribine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mizoribine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pregnenolone.Experimental, Investigational
ProbenecidThe serum concentration of Mizoribine can be increased when it is combined with Probenecid.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Mizoribine is combined with Proglumetacin.Experimental
PromazineThe serum concentration of Promazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Mizoribine.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Mizoribine.Approved, Investigational
PropiopromazineThe serum concentration of Propiopromazine can be increased when it is combined with Mizoribine.Vet Approved
PropranololMizoribine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mizoribine.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mizoribine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mizoribine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mizoribine.Vet Approved
Protein CMizoribine may increase the anticoagulant activities of Protein C.Approved
Protein S humanMizoribine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMizoribine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMizoribine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Mizoribine.Investigational
PuromycinMizoribine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mizoribine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mizoribine.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mizoribine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mizoribine.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mizoribine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Mizoribine.Approved, Experimental, Investigational
ReviparinMizoribine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMizoribine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Mizoribine.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Risedronate.Approved, Investigational
RivaroxabanMizoribine may increase the anticoagulant activities of Rivaroxaban.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Mizoribine.Approved
RosoxacinMizoribine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Mizoribine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Mizoribine.Approved
RufloxacinMizoribine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinMizoribine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mizoribine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Mizoribine.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Mizoribine.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mizoribine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mizoribine.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Mizoribine.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Mizoribine.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Mizoribine is combined with Serrapeptase.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mizoribine.Approved
SisomicinMizoribine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinMizoribine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Mizoribine.Approved
SotalolMizoribine may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMizoribine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMizoribine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinMizoribine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mizoribine.Approved
SpironolactoneMizoribine may decrease the antihypertensive activities of Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Mizoribine.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Mizoribine.Investigational
StreptomycinMizoribine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMizoribine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mizoribine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mizoribine.Approved
SulodexideMizoribine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mizoribine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Mizoribine.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Suxibuzone.Experimental
TacrolimusMizoribine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mizoribine.Approved
TalinololMizoribine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mizoribine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mizoribine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mizoribine.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Mizoribine.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mizoribine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mizoribine.Approved, Investigational
TemafloxacinMizoribine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mizoribine.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mizoribine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Mizoribine.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Mizoribine.Approved
TertatololMizoribine may decrease the antihypertensive activities of Tertatolol.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Mizoribine.Investigational
ThiazinamThe serum concentration of Thiazinam can be increased when it is combined with Mizoribine.Experimental
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Mizoribine.Withdrawn
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mizoribine.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mizoribine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMizoribine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tixocortol.Approved
TobramycinMizoribine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibMizoribine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mizoribine.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mizoribine.Approved
TorasemideMizoribine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mizoribine.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Mizoribine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mizoribine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mizoribine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mizoribine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mizoribine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMizoribine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Mizoribine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mizoribine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Mizoribine.Approved
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Mizoribine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Mizoribine.Investigational
TrovafloxacinMizoribine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMizoribine may increase the anticoagulant activities of Troxerutin.Investigational
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mizoribine.Approved
ValrubicinMizoribine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mizoribine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mizoribine.Approved
WarfarinMizoribine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMizoribine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Mizoribine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mizoribine.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mizoribine.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Mizoribine.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Mizoribine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Mizoribine.Withdrawn
Zoptarelin doxorubicinMizoribine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinMizoribine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Mizoribine.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB41934
PubChem Compound
104762
PubChem Substance
347828830
ChemSpider
94571
BindingDB
68669
ChEBI
31858
ChEMBL
CHEMBL245019
HET
MZR
PDB Entries
3b1n

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentRheumatoid Arthritis1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentNephritis, Lupus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility36.1 mg/mLALOGPS
logP-2.3ALOGPS
logP-2ChemAxon
logS-0.86ALOGPS
pKa (Strongest Acidic)8.19ChemAxon
pKa (Strongest Basic)2.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area151.06 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity55.55 m3·mol-1ChemAxon
Polarizability23.58 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-ribosyl-imidazolecarboxamides. These are organic compounds containing the imidazole ring linked to a ribose ring through a 1-2 bond.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Imidazole ribonucleosides and ribonucleotides
Sub Class
1-ribosyl-imidazolecarboxamides
Direct Parent
1-ribosyl-imidazolecarboxamides
Alternative Parents
Glycosylamines / Pentoses / 2-heteroaryl carboxamides / Carbonylimidazoles / N-substituted imidazoles / Vinylogous amides / Vinylogous acids / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols
show 8 more
Substituents
1-ribosyl-imidazolecarboxamide / Glycosyl compound / N-glycosyl compound / Pentose monosaccharide / 2-heteroaryl carboxamide / Imidazole-4-carbonyl group / N-substituted imidazole / Monosaccharide / Azole / Tetrahydrofuran
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:14 / Updated on November 09, 2017 05:10